Vitura Health Limited (VIT) Fair Value & Analysis
Healthcare · AU · Market cap A$21.2M
Fair value as of: Jun 26, 2026
Analysis
Vitura Health Limited (VIT) currently trades at A$0.0210, while our model-based Fair Value estimate is A$0.0397 — implying the stock looks roughly 89.0% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a therapy clinic that offers telehealth consultations. It also offers psychedelics under the Cortexa brand; Adaya which provides hybrid formulations and Australian-cultivated products; candor medical that provides care to patients; and inscape, which offers crafted formulations for individual needs. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. Vitura Health Limite…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Vitura Health Limited (VIT) undervalued?
What is the fair value of VIT?
What is the quality score of VIT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.